{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["14(3)"],"submitter":["Kim DJ"],"funding":["BI Lilly Alliance"],"pubmed_abstract":["<h4>Aims/introduction</h4>The EMPA-REG OUTCOME® trial demonstrated benefits of empagliflozin, a sodium-glucose cotransporter-2 inhibitor (SGLT2i), on cardiovascular, renal outcomes and all-cause mortality in patients with type 2 diabetes and established cardiovascular disease. The EMPRISE study program evaluates how these effects translate in a broad population of patients with type 2 diabetes in routine clinical care across countries.<h4>Materials and methods</h4>The study included patients ≥18 years with type 2 diabetes initiating empagliflozin or any dipeptidyl peptidase-4 inhibitors (DPP-4i) from large administrative databases in Japan, South Korea, and Taiwan. Propensity score-matched (1:1) 'as-treated' analyses comparing the risk of cardiovascular outcomes and all-cause mortality bet"],"journal":["Journal of diabetes investigation"],"pagination":["417-428"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9951576"],"repository":["biostudies-literature"],"pubmed_title":["Empagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in routine care in East Asia: Results from the EMPRISE study."],"pmcid":["PMC9951576"],"pubmed_authors":["Lee S","Kim DJ","EMPRISE East Asia Study Group","Ha KH","Node K","Seino Y","Nangaku M","Yabe D","Deruaz-Luyet A","Kyaw MH","Sheu WH","Chung WJ","Lei W","Saarelainen L","Yasui A","Tan EC"],"additional_accession":[]},"is_claimable":false,"name":"Empagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in routine care in East Asia: Results from the EMPRISE study.","description":"<h4>Aims/introduction</h4>The EMPA-REG OUTCOME® trial demonstrated benefits of empagliflozin, a sodium-glucose cotransporter-2 inhibitor (SGLT2i), on cardiovascular, renal outcomes and all-cause mortality in patients with type 2 diabetes and established cardiovascular disease. The EMPRISE study program evaluates how these effects translate in a broad population of patients with type 2 diabetes in routine clinical care across countries.<h4>Materials and methods</h4>The study included patients ≥18 years with type 2 diabetes initiating empagliflozin or any dipeptidyl peptidase-4 inhibitors (DPP-4i) from large administrative databases in Japan, South Korea, and Taiwan. Propensity score-matched (1:1) 'as-treated' analyses comparing the risk of cardiovascular outcomes and all-cause mortality bet","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Mar","modification":"2025-04-22T03:33:03.476Z","creation":"2025-04-05T20:46:13.691Z"},"accession":"S-EPMC9951576","cross_references":{"pubmed":["36716212"],"doi":["10.1111/jdi.13959"]}}